Search Results

THE MEDCOMP EXCELL™ SPLIT-TIP CATHETER IS INDICATED FOR USE IN ATTAINING LONG TERM VASCULAR ACCESS FOR HEMODIALYSIS AND APHERESIS. IT MAY BE INSERTED PERCUTANEOUSLY AND IS PRIMARILY PLACED IN THE INTERNAL JUGULAR VEIN. ALTERNATE INSERTION SITES INCLUDE THE SUBCLAVIAN VEIN AS REQUIRED. CATHETERS GREATER THAN 40CM ARE INTENDED FOR FEMORAL VEIN INSERTION.

The Medcomp Excell™ Split-Tip Catheter is a 15F polyurethane, double lumen catheter used to remove and return blood through two, segregated furnen passages. Both lumens are "D" shaped, open at the distal tip, with two side holes. The distal venous lumen is tapered and extends beyond the arterial lumen to reduce recirculation. The fixed polyester cuff allows for tissue ingrowth for long-term placement. The arterial and venous lumens now are designed to be split, or peeled apart, prior to insertion to provide two free-floating lumens within the vessel. The lumens are connected to the extensions via a soft pliable hub with suture wing. The arterial and venous extensions are identified by red and blue luer connectors and clamps. Priming volume information is printed on the I.D. rings for ease in identification.

Here's an analysis of the provided text regarding the acceptance criteria and study for the Medcomp Excell™ Split-Tip Catheter:

Acceptance Criteria and Device Performance

The provided document describes the modification of a legally marketed device and asserts its substantial equivalence to predicate devices. The "acceptance criteria" are implied by the performance data demonstrating "substantial equivalence." However, explicit, quantifiable acceptance criteria with pass/fail thresholds are not stated in the document.

The performance data focuses on demonstrating that the modified device performs similarly to existing, legally marketed devices for hemodialysis and apheresis treatments.

Here's a table based on the provided information:

Note regarding "Acceptance Criteria": The document does not explicitly list quantified acceptance criteria (e.g., "recirculation must be less than 5%"). Instead, it states that the device was tested to demonstrate "substantial equivalence" to predicate devices for specific performance characteristics. This implies that the acceptance criteria were met if the device's performance in these tests was comparable to that of the predicate devices, falling within an acceptable range for the intended use.

Study Details (Based on the provided text)

1. Sample size used for the test set and the data provenance:

   • Sample Size: Not specified. The study involved "in vitro performance data," which typically refers to laboratory testing and might involve multiple samples of the device, but the exact number is not provided.
   • Data Provenance: The study was an in vitro performance test, meaning it was conducted in a laboratory setting, not on human subjects. The country of origin for the data is not explicitly mentioned, but the submitter is a U.S. company (Harleysville, PA). It is by definition a prospective study in that the testing was performed on the device designed for submission.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • Number of Experts: Not applicable. This was an in vitro performance study comparing the device to predicate devices. There was no "ground truth" established by human experts in the context of clinical observations or diagnoses. Instead, the performance parameters of the device were measured and compared.
   • Qualifications of Experts: Not applicable for establishing ground truth.

3. Adjudication method for the test set:

   • Adjudication Method: Not applicable. As an in vitro performance study, there was no need for expert adjudication of results in the way it would be required for clinical image analysis or diagnostic studies. The results were likely derived from standardized test protocols and measurements.

4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • MRMC Study: No, an MRMC comparative effectiveness study was not done. This device is a medical catheter, not an AI software intended for interpretation by human readers.
   • Effect Size of AI assistance: Not applicable.

5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

   • Standalone Performance: Not applicable. This is a physical medical device, not an algorithm. Therefore, "standalone" performance for an algorithm doesn't apply. The in vitro testing represents the "standalone" performance of the physical device in a controlled environment.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

   • Type of Ground Truth: Not applicable in the traditional sense of clinical "ground truth." For in vitro performance studies, the "ground truth" is typically defined by standardized physical measurements, engineering specifications, and the established performance characteristics of the predicate devices. The "truth" is that the device should perform comparably to its predicates under controlled test conditions.

7. The sample size for the training set:

   • Sample Size for Training Set: Not applicable. This is a physical medical device, not a machine learning model. There is no concept of a "training set" for the device itself.

8. How the ground truth for the training set was established:

   • Ground Truth for Training Set: Not applicable for the reasons stated above (physical device, no machine learning model).

Ask a specific question about this device

THE MEDCOMP ASH SPLIT-CATH II IS INDICATED FOR USE IN ATTAINING LONG-TERM VASCULAR ACCESS FOR HEMODIALYSIS AND APHERESIS. IT MAY BE INSERTED PERCUTANEOUSLY AND IS PRIMARILY PLACED IN THE INTERNAL JUGULAR VEIN. ALTERNATE INSERTION SITES INCLUDE THE SUBCLAVIAN VEIN AS REQUIRED. CATHETERS GREATER THAN 40cm ARE INTENDED FOR FEMORAL VEIN INSERTION.

The Medcomp Ash Split-Cath II is a polyurethane, double lumen catheter used to remove and return blood through two-segregated lumen passages. Both lumens are "D" shaped, tapered at the distal tip, with eight side holes. The distal venous lumen extends beyond the arterial lumen to reduce recirculation. The fixed polyester cuff allows for tissue ingrowth for long term placement. The arterial and venous lumens are designed to be split, or peeled apart, prior to insertion to provide two free-floating lumens within the vessel. The side holes are orientated to allow 360-degree arterial uptake and venous return. The lumens are connected to the extensions via a soft pliable hub with suture wing. Red and blue luer connectors and clamps identify the arterial and venous extensions. Priming volume information is printed an identification ring housed within the extension line clamp.

The provided text describes a 510(k) premarket notification for the Medcomp Ash Split-Cath II Hemodialysis Catheter. This is a medical device, not an AI/ML-driven solution or a diagnostic tool that would typically involve acceptance criteria based on metrics like sensitivity, specificity, or reader performance. Therefore, many of the requested points are not applicable.

The "acceptance criteria" for this type of medical device submission are typically met by demonstrating substantial equivalence to a previously legally marketed predicate device. This is achieved through performance data showing that the new device is as safe and effective as the predicate.

Here's an analysis based on the information provided:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

This is not applicable in the context of this 510(k) submission. The "test set" primarily refers to in vitro performance data of the device itself, comparing its physical and functional properties to the predicate. There is no mention of a "test set" in the sense of clinical data or patient data. The provenance of the in vitro test data is not specified (e.g., country of origin), but it would have been generated in a lab setting. It is not retrospective or prospective patient data.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts

Not applicable. Ground truth for a physical device's performance (e.g., tensile strength, flow rate) is established through standardized engineering and laboratory testing protocols, not human expert consensus.

4. Adjudication Method for the Test Set

Not applicable. Adjudication methods (like 2+1, 3+1) are used for clinical assessments or image interpretations involving human readers. The performance data here is based on objective laboratory measurements.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, if so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This device is a catheter, not an AI-assisted diagnostic tool.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This is not an algorithm.

7. The Type of Ground Truth Used (expert consensus, pathology, outcomes data, etc.)

The "ground truth" for this device's performance relies on objective physical and mechanical testing standards (e.g., tensile strength, flow rate measurements as per ISO 10993 for biocompatibility) compared to the performance of the predicate device.

8. The Sample Size for the Training Set

Not applicable. This is not an AI/ML model that requires training data.

9. How the Ground Truth for the Training Set Was Established

Not applicable. This is not an AI/ML model.

Ask a specific question about this device